Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

China flag China · Delayed Price · Currency is CNY
85.50
-2.38 (-2.71%)
Jan 22, 2026, 3:00 PM CST
29.35%
Market Cap23.26B
Revenue (ttm)742.28M
Net Income (ttm)-133.34M
Shares Out264.71M
EPS (ttm)-0.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,075,055
Average Volume3,391,781
Open87.88
Previous Close87.88
Day's Range84.98 - 88.88
52-Week Range62.68 - 134.17
Beta0.31
RSI33.27
Earnings DateMar 28, 2026

About SHA:688266

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration clinical trial stages, such as gecacitinib hydroch... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 910
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688266
Full Company Profile

Financial Performance

In 2024, SHA:688266's revenue was 532.95 million, an increase of 37.91% compared to the previous year's 386.44 million. Losses were -137.83 million, -50.52% less than in 2023.

Financial Statements